Alnylam suspends bleeding disorder trial dosing after patient death

(Reuters) - U.S. drug developer Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies following a patient's death.